Physician profile
Jamie E Mckenzie
NPI 1104953546
$24,786.08
in general payments reported to CMS, 2019-2025
20 companies · $1,602 in 2025
The $1,602 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.16 · 2020: $36.77 · 2021: $26.64 · 2022: $479 · 2023: $3,315 · 2024: $19K · 2025: $1,602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Consulting Fee: $4,848 · Food and Beverage: $2,392 · Long Term Medical Supply Or Device Loan: $2,113 · Travel and Lodging: $312 · Education: $5.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,480.00 |
| Consulting Fee | $4,847.50 |
| Food and Beverage | $2,391.51 |
| Long Term Medical Supply Or Device Loan | $2,113.03 |
| Travel and Lodging | $311.62 |
| Education | $5.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17,991.94 | 2022-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $2,216.75 | 2022-2025 | |
| Pfizer INC. | $1,507.91 | 2019-2024 | |
| Stemline Therapeutics INC. | $1,354.26 | 2023-2024 | Orserdu |
| Daiichi Sankyo INC. | $406.87 | 2022-2025 | Enhertu |
| Tersera Therapeutics LLC | $305.37 | 2024-2025 | Zoladex |
| Lilly USA, LLC | $257.79 | 2021-2024 | Verzenio, Jaypirca |
| Ge Healthcare | $217.23 | 2022-2024 | |
| Inspire Medical Systems, INC. | $101.27 | 2025 | Inspire |
| Incyte Corporation | $100.00 | 2024 | Pemazyre, Monjuvi, Jakafi |
| Janssen Biotech, INC. | $91.91 | 2019-2020 | |
| Puma Biotechnology, INC. | $81.32 | 2023-2024 | Nerlynx |
| Genentech USA, INC. | $52.90 | 2023-2024 | Phesgo, Perjeta, Kadcyla |
| Genentech, INC. | $38.48 | 2024 | Itovebi |
| Tempus Ai, INC | $20.35 | 2024 | Xt Cdx |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12.43 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $11.96 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Rigel Pharmaceuticals, INC. | $5.42 | 2023 | Tavalisse, Rezlidhia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Mckenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.